Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sajitha Sachchithanantham

Showing results (21-30 of 58) with videos related to

Pageof 6
Sort By:
Blood|September 23, 2015
Natural history and outcome of light chain deposition diseaseRabya H Sayed, Ashutosh D Wechalekar, Janet A Gilbertson, et al.
British Journal of Haematology|May 10, 2017
Role of implantable intracardiac defibrillators in patients with cardiac immunoglobulin light chain amyloidosisTamer Rezk, Carol J Whelan, Helen J Lachmann, et al.
Haematologica|January 7, 2018
Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosisRicha Manwani, Darren Foard, Shameem Mahmood, et al.
British Journal of Haematology|August 15, 2019
A 24-year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United KingdomFaye A Sharpley, Aviva Petrie, Shameem Mahmood, et al.
Blood|June 22, 2018
Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustineRicha Manwani, Sajitha Sachchithanantham, Shameem Mahmood, et al.
European Journal of Haematology|June 5, 2020
The value of screening biopsies in light-chain (AL) and transthyretin (ATTR) amyloidosisOliver C Cohen, Faye Sharpley, Janet A Gilbertson, et al.
Blood Cancer Journal|June 22, 2021
Impact of early response on outcomes in AL amyloidosis following treatment with frontline BortezomibSriram Ravichandran, Oliver C Cohen, Steven Law, et al.
British Journal of Haematology|June 30, 2021
Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real-world longitudinal dataSriram Ravichandran, Oliver C Cohen, Steven Law, et al.
British Journal of Haematology|May 5, 2022
A UK consensus algorithm for early treatment modification in newly diagnosed systemic light-chain amyloidosisSriram Ravichandran, Shameem Mahmood, Brenden Wisniowski, et al.
British Journal of Haematology|June 17, 2014
Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimensShameem Mahmood, Christopher P Venner, Sajitha Sachchithanantham, et al.
Pageof 6

Showing results (21-30 of 58) with videos related to

Sort By:
Pageof 6
Blood|September 23, 2015
Natural history and outcome of light chain deposition diseaseRabya H Sayed, Ashutosh D Wechalekar, Janet A Gilbertson, et al.
British Journal of Haematology|May 10, 2017
Role of implantable intracardiac defibrillators in patients with cardiac immunoglobulin light chain amyloidosisTamer Rezk, Carol J Whelan, Helen J Lachmann, et al.
Haematologica|January 7, 2018
Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosisRicha Manwani, Darren Foard, Shameem Mahmood, et al.
British Journal of Haematology|August 15, 2019
A 24-year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United KingdomFaye A Sharpley, Aviva Petrie, Shameem Mahmood, et al.
Blood|June 22, 2018
Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustineRicha Manwani, Sajitha Sachchithanantham, Shameem Mahmood, et al.
European Journal of Haematology|June 5, 2020
The value of screening biopsies in light-chain (AL) and transthyretin (ATTR) amyloidosisOliver C Cohen, Faye Sharpley, Janet A Gilbertson, et al.
Blood Cancer Journal|June 22, 2021
Impact of early response on outcomes in AL amyloidosis following treatment with frontline BortezomibSriram Ravichandran, Oliver C Cohen, Steven Law, et al.
British Journal of Haematology|June 30, 2021
Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real-world longitudinal dataSriram Ravichandran, Oliver C Cohen, Steven Law, et al.
British Journal of Haematology|May 5, 2022
A UK consensus algorithm for early treatment modification in newly diagnosed systemic light-chain amyloidosisSriram Ravichandran, Shameem Mahmood, Brenden Wisniowski, et al.
British Journal of Haematology|June 17, 2014
Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimensShameem Mahmood, Christopher P Venner, Sajitha Sachchithanantham, et al.
Pageof 6